Home / Pipeline

Our Product Development Pipeline

Our robust product development pipeline is built on a portfolio of proprietary and patented technology. Driven by Lisata’s vision and mission, our pipeline programs are grounded in rational science to identify and treat patients most likely to respond to our targeted therapies. Click on each program to learn more.

CendR Platform® Programs

The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer agents to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.

IndicationPre ClinicalPhase 1Phase 2Phase 3

Indication: First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand)
First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand)
Phase 2
Gemcitabine/nab-paclitaxel + LSTA1 (China)
Gemcitabine/nab-paclitaxel + LSTA1 (China)
Phase 1
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia)
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia)
Phase 1

Indication: Pancreatic, Colon, and Appendiceal Cancers

LSTA1 + FOLFIRINOX + panitumumab* (U.S.)
Pancreatic, Colon, and Appendiceal Cancers
LSTA1 + FOLFIRINOX + panitumumab* (U.S.)
Phase 1

Indication: Various Solid Tumors

SoC with LSTA1 or placebo (U.S.)
Various Solid Tumors
SoC with LSTA1 or placebo (U.S.)
Phase 2
TPN Development Candidate (U.S.)
TPN Development Candidate (U.S.)
Phase 1
LSTA1 has been granted Fast Track and Orphan Drug Designations by the U.S. FDA in pancreatic ductal adenocarcinoma (PDAC)

CD34+ Platform Programs

Lisata’s proprietary CD34+ cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Through the administration of CD34+ cell therapy, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted areas.

IndicationPre ClinicalPhase 1Phase 2Phase 3

Indication: Coronary Microvascular Dysfunction

XOWNA® (LSTA16) (U.S.)
Coronary Microvascular Dysfunction
XOWNA® (LSTA16) (U.S.)
Phase 2

Indication: Critical Limb Ischemia and Buerger’s Disease

HONEDRA® (LSTA12) (Japan)
Critical Limb Ischemia and Buerger’s Disease
HONEDRA® (LSTA12) (Japan)
Phase 2

Indication: Diabetic Kidney Disease

LSTA201 (U.S.)
Diabetic Kidney Disease
LSTA201 (U.S.)
Phase 1